Reports Q4 revenue $25.82M, consensus $25.78M. "Our Simoa technology continues to be on the forefront of research, testing, therapeutic trials and has been an integral part of recent advances in Alzheimer’s disease. In order to best capture and lead in this area, two quarters ago we began a corporate transformation and we’re pleased to announce the program is on track, with good progress quarter over quarter," said Masoud Toloue, president and CEO of Quanterix.
Published first on TheFly